ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
January 21, 2025 19:00 ET | Source: ArriVent BioPharma, Inc. Exclusive global…
Stmm’s Continuous Bioreactor Increases Antibody Productivity by up to 30x in European and American Pilots
Pilot runs in Europe and South America show breakthrough efficiency in monoclonal…
Numab Therapeutics and Kaken Pharmaceutical Enter Collaborationand Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
Numab to receive R&D funding for the preclinical development of ND081 Kaken…